[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623990":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":46,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":72,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T Cell Therapy Patients","EXPERIMENTAL","40 enrolled participants will complete:\n\n* Baseline visit\n* Daily study visits during hospitalization, then via phone: 2x weekly on days 14 - 21, then weekly on days 21 - 30\n* 90 Day follow up visit",[13],"Behavioral: DCog Short",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","DCog Short","An iPad-based cognitive assessment instrument to evaluate neurotoxicity and consisting of a series of tests that measure various aspects of cognitive function. After hospital discharge, participants will be provided with iPads which will be returned at the 90 day follow up visit.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Jon Arnason, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","(617) 667-9920","jarnason@bidmc.harvard.edu",[31],{"facility":5,"status":20,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Boston","Massachusetts","02215","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-71.05977,42.35843,{"lat":41,"lon":40},[44,45],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Jon Arnason","Principal Investigator","100623990","assessing-dcog-short-for-neurotoxicity-in-car-t-100623990",false,"NCT07403812","Assessing DCog Short for Neurotoxicity in CAR-T","Assessing the Performance of \"DCog Short\", an iPad-Based Tool for Neurotoxicity Evaluation in CAR-T Cell Therapy Patients: A Pilot Study","Inclusion Criteria:\n\n* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.\n* Visual acuity of 20\u002F100 or better.\n\nExclusion Criteria:\n\n* patients \\\u003C 18 years old\n* pregnant women\n* prisoners\n* adults unable to consent,\n* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad","ALL","18 Years",{"count":59,"type":60},40,"ESTIMATED","INTERVENTIONAL",[63],"NA","The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.",[66,67,68,69],"Neurotoxicity","Neurotoxicity Syndromes","Hematologic Malignancy","Immune Effector Cell Associated Neurotoxicity Syndrome",[66,71,68,69],"Neurotoxicity Syndrome","NOT_YET_RECRUITING","2026-02-04",{"date":75,"type":76},"2026-02-11","ACTUAL",{"date":78,"type":60},"2026-07",{"date":80,"type":60},"2027-08-31",{"name":5,"class":6},1]